RXRX vs. KYMR, SDGR, PTCT, RCUS, VIE, PCVX, RVMD, EXEL, HALO, and CRSP
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Kymera Therapeutics (KYMR), Schrödinger (SDGR), PTC Therapeutics (PTCT), Arcus Biosciences (RCUS), Viela Bio (VIE), Vaxcyte (PCVX), Revolution Medicines (RVMD), Exelixis (EXEL), Halozyme Therapeutics (HALO), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Kymera Therapeutics (NASDAQ:KYMR) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Kymera Therapeutics has a net margin of -194.67% compared to Kymera Therapeutics' net margin of -765.90%. Recursion Pharmaceuticals' return on equity of -31.92% beat Kymera Therapeutics' return on equity.
Kymera Therapeutics currently has a consensus price target of $42.70, indicating a potential upside of 32.98%. Recursion Pharmaceuticals has a consensus price target of $14.33, indicating a potential upside of 73.11%. Given Kymera Therapeutics' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Kymera Therapeutics.
In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.73 beat Recursion Pharmaceuticals' score of 0.62 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Kymera Therapeutics received 19 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 51.22% of users gave Recursion Pharmaceuticals an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
Kymera Therapeutics has a beta of 2.31, meaning that its share price is 131% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
Kymera Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Kymera Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Recursion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Recursion Pharmaceuticals Competitors List
Related Companies and Tools
